Corestem, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Seongnam Korea, Republic of (2003)

Organization Overview

First Clinical Trial
2011
NCT01363401
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Corestem, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Atrophy (Phase 1)

Central Nervous System Diseases (Phase 1)

Lupus Nephritis (Phase 1)

Motor Neuron Disease (Phase 2)

Multiple System Atrophy (Phase 1)

Nephritis (Phase 1)

Nervous System Diseases (Phase 1)

Neurodegenerative Diseases (Phase 1)

Neuromuscular Diseases (Phase 1)

Sclerosis (Phase 2)

Shy-Drager Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5